;

Search Results:

Showing of 50

CLINICAL TRIAL18329

A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18876

A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 alone and in Combination with Cytarabine (Ara-C) in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome with Wild-Type TP53

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18783

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18539

A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18950

A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18926

The National Myelodysplastic Syndromes (MDS) Study

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL18982

The Roles of Education and Patient Engagement to Improve Symptom Management and the Quality of Life for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19151

A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19149

A Phase 1/2, Open Label, Multicenter Study To Assess The Safety And Tolerability Of Durvalumab (Anti-Pd-L1 Antibody) As Monotherapy And In Combination Therapy In Subjects With Lymphoma Or Chronic Lymphocytic Leukemia

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19150

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphomawith Previously Treated Diffuse Large B-Cell Lymphoma

Cancer Type: Malignant Hematology

View Trial Details

CLINICAL TRIAL19324

An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects with B-cell Lymphomas or Advanced Solid Tumors

Cancer Type: Malignant Hematology

View Trial Details